Diagnostic Accuracy of Oral Mucosal Transudate Tests Compared with Blood-Based Rapid Tests for HIV Among Children Aged 18 Months to 18 Years in Kenya and Zimbabwe

Chido Dziva Chikwari, MSc,a,b,* Irene N. Njuguna, MBChB, MPH, PhDc,d,* Jillian Neary, MPH,e Crissi Rainer, MSc,f Belinda Chihota, MSc,g Jennifer A. Slyker, MSc, PhD,c,e David A. Katz, MPH, PhD,h Dalton C. Wamalwa, MBChB, MMEd, MPH,i Laura Oyiengo, MBChB, MMEd,j Tsitsi Bandason, MSc,b Grace McHugh, MD,b Eihel Dauya, MPH,b Hilda Mujuru, MBChB, MMEd,k Kearsley A. Stewart, PhD,f Grace C. John-Stewart, MD, MPH, PhD,e Rashida A. Ferrand, MB BS, PhD,ab and Anjuli D. Wagner, MPH, PhDc

Background: Gaps persist in HIV testing for children who were not tested in prevention of mother-to-child HIV transmission programs. Oral mucosal transudate (OMT) rapid HIV tests have been shown to be highly sensitive in adults, but their performance has not been established in children.

Methods: Antiretroviral therapy-naive children aged 18 months to 18 years in Kenya and Zimbabwe were tested for HIV using rapid OraQuick ADVANCE Rapid HIV-1/2 Antibody test on oral fluids (OMT) and blood-based rapid diagnostic testing (BBT). BBT followed Kenyan and Zimbabwean national algorithms. Sensitivity and specificity were calculated using the national algorithms as the reference standard.

Results: A total of 1776 children were enrolled; median age was 7.3 years (interquartile range: 4.7–11.6). Among 71 children positive by BBT, all 71 were positive by OMT (sensitivity: 100% [97.5% confidence interval (CI): 94.9% to 100%]). Among the 1705 children negative by BBT, 1703 were negative by OMT (specificity: 99.9% [95% CI: 99.6% to 100.0%]). Due to discrepant BBT and OMT results, 2 children who initially tested BBT-negative and OMT-positive were subsequently confirmed positive within 1 week by further tests. Excluding these 2 children, the sensitivity and specificity of OMT compared with those of BBT were each 100% (97.5% CI: 94.9% to 100% and 99.8% to 100%, respectively).

Received for publication May 6, 2019; accepted July 10, 2019.

From the aClinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom; bBiomedical Research and Training Institute, Harare, Zimbabwe; cDepartment of Epidemiology, University of Washington, Seattle, WA; dResearch and Programs, Kenyatta National Hospital, Nairobi, Kenya; eDepartment of Global Health, University of Washington, Seattle, WA; fDuke Global Health Institute, Duke University, Durham, NC; gCentre for Infectious Disease Research in Zambia, Lusaka, Zambia; hDepartment of Medicine, Division of Allergy and Infectious Diseases, School of Medicine, University of Washington, Seattle, WA; iDepartment of Paediatric and Child Health, University of Nairobi, Nairobi, Kenya; National AIDS & STI Control Programme, Ministry of Health, Nairobi, Kenya; jUniversity of Zimbabwe College of Health Sciences, Harare, Zimbabwe; and kDepartments of Medicine and Pediatrics, University of Washington, Nairobi, Kenya.

Supported by Wellcome Trust grant code 206316/Z/17/Z. The study in Zimbabwe was jointly funded by the Duke Global Health Institute, the UK Medical Research Council (UK MRC), and the UK Department for International Development (DFID) under the MRC/DFID concordat agreement and is also part of the EDCTP2 program supported by the European Union (MR/P012681/1). The Saliva Testing and Video Information to Expand Uptake of Pediatric HIV Testing (STEP-UP) study was funded by the National Institutes of Health (NIH; P30 AI027757 [CFAR New Investigator Award; PI: A.D.W.]) and the Thrasher Research Foundation (A119882). J.N., D.A.K., J.N., and A.D.W. were supported by P30 AI027757. A.D.W. was also supported by A119882. I.N.N. was supported by Fogarty International Centre (FIC) D43TW009783. This publication was supported by the University of Washington Global Center for the Integrated Health of Women, Adolescents, and Children (Global WACH). This publication was funded in part by the University of Washington/Fred Hutch Center for AIDS Research, and NIH funded program under award number AI027757, which is supported by the following NIH Institutes and Centers: NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIAID, NIGMS, NIDDK. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Data previously presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 6, 2019; Seattle Washington.

The authors have no conflicts of interest to disclose.

C.D.C., I.N.N., and A.D.W. developed the first draft of the manuscript and conducted the data analysis. Zimbabwe: C.R. developed the study protocol and was assisted by B.C. who developed data collection tools and standard operating procedures. R.A.F., H.M., G.M. and K.A.S. supervised the design of the study. T.B. managed the dataset. G.M., C.D.C., B.C., and E.D. supervised field staff. Kenya: A.D.W., I.N.N., J.N., G.C.J.-S., J.A.S., D.A.K. and D.C.W. developed the protocol. A.D.W. and I.N.N. obtained grant funding. A.D.W., I.N.N. and J.N. developed study material and supervised data collection. All co-authors revised and approved the final draft of this manuscript.

* C.D.C. and I.N.N. joint first authors.

A donation of 3000 test kits was received from OraSure technologies for the Zimbabwe site.

Correspondence to: Chido Dziva Chikwari, Biomedical Research and Training Institute, 10 Seagrave Road, Avondale, Harare, Zimbabwe (e-mail: Chido.DzivaChikwari@lshtm.ac.uk).

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conclusions: Compared to national algorithms, OMT did not miss any HIV-positive children. These data suggest that OMTs are valid in this age range. Future research should explore the acceptability and uptake of OMT by caregivers and health workers to increase pediatric HIV testing coverage.

Key Words: HIV, children, pediatric, oral HIV testing, diagnostic, saliva HIV testing

(J Acquir Immune Defic Syndr 2019;82:368–372)

INTRODUCTION

The HIV pandemic has heavily affected children with over 1.8 million children (<15 years) living with HIV and 180,000 newly infected in 2017.1 Prompt diagnosis and initiation on antiretroviral therapy (ART) is associated with decreased morbidity and mortality2,3 and improved developmental outcomes4,5; however, gaps remain in diagnosis, particularly among older children and adolescents.6

World Health Organization (WHO) recommendations endorse rapid antibody-based HIV tests for diagnosis of individuals >18 months.7 Blood-based HIV tests (BBT) are used globally. In addition, oral mucosal transudate (OMT) rapid HIV tests allow for sample collection that is less invasive, are more acceptable to clients, poses fewer risks to health care workers (HCW), and may increase testing uptake.8,10

The Food and Drug Administration approved the OraQuick OMT in 2004 for testing by health providers for individuals >12 years.11 In 2016, the OraQuick HIV Self-Test received WHO prequalification and it is now recommended by WHO as a screening test for HIV.12 OMT has high sensitivity and specificity in detecting HIV antibodies in adults and older adolescents.7,10 A meta-analysis comparing OMT with BBT in adults reported a pooled sensitivity of 98.0% and specificity of 99.7% for OMT.10 OMT has not been validated in children.

We evaluated the diagnostic performance of OMT compared with routine BBT in children and adolescents aged 18 months to 18 years in Kenya and Zimbabwe.

METHODS

Setting and Participants

This analysis includes pooled data from 2 studies in Kenya and Zimbabwe that include parallel point-of-care diagnostic OMT and BBT to assess sensitivity and specificity of OMT among children and adolescents. Data were combined to increase precision of sensitivity and specificity estimates, as the number of newly diagnosed HIV-positive children in both settings has reduced with the scale-up of pediatric HIV prevention and treatment programs.

Zimbabwe

This analysis was nested within the “Bridging the Gap in HIV Testing and Care for Children in Zimbabwe” (B-GAP Project) whose aim is to evaluate index-linked testing for pediatric case detection. Study participants were children and adolescents of unknown HIV status, aged 2–18 years, attending any health services in the participating hospitals and primary health care clinics.

Kenya

The “Saliva Testing and Video Information to Expand Uptake of Pediatric HIV Testing” (STEP-UP) study enrolled children aged 18 months to 12 years. Two recruitment streams were used. First, children of HIV-positive adults attending HIV clinics who were tested for HIV within a randomized controlled trial of financial incentives for index case testing (FIT trial; NCT03049917)13 were recruited after determining HIV status using BBT within the trial. Second, children from outpatient clinics were recruited after HIV testing using BBT within routine testing; here children who tested BBT positive were oversampled.

Procedures

Zimbabwe

Testing followed the national algorithm14: first, BBT by Determine (Alere Determine HIV-1/2 Ag/Ab Combo; Abbott, Chicago, IL) (fourth generation), followed by First Response (First Response HIV-1-2; Premier Medical Corporation Ltd, Kachigam, India) (third generation), if Determine was reactive. In the case of 2 reactive BBTs, the same 2 BBTs were performed by a different provider to confirm a positive diagnosis. In the case of discordant BBTs, both tests were repeated. If discordance persisted, a third test, CHEMBIO was performed (CHEMBIO HIV 1/2 STAT-PAK Assay; CHEMBIO Diagnostic Systems, Inc., New York, NY). If this third test was positive, the result was reported as inconclusive and a retest conducted in 14 days. OMT was conducted by clinic staff blinded to BBT results.

Kenya

The national algorithm mirrored that in Zimbabwe with the following exceptions: the Determine HIV test was third instead of fourth generation and DNA PCR from dry blood spot specimens was the third test and was considered conclusive.14–16 In addition BBT was conducted by research staff for those enrolled in the FIT trial and non-research staff for those enrolled from routine testing points. Research staff performed OMT and were not blinded to BBT results.

The reference standard used for our study was the HIV status as per the national algorithm of each country.

OMT

In Zimbabwe and Kenya, OMT sample collection and processing was performed bedside by qualified HIV testing lay providers who are typically lower than nurse level providers and are responsible for HIV testing in both countries. The qualification for these providers is a standard national training for HIV services conducted over 2 weeks. Testing was conducted according to manufacturer details (OraQuick ADVANCE Rapid HIV-1/2 Antibody Test; Or- aSure Technologies, Inc., Bethlehem, PA), whereby the research staff collected an oral fluid sample from the participants by running the test device between the lips and outer gums of the client once on top and once at the bottom
and then place the test device pad directly into the reaction fluid immediately after collection. OMT results were read once between 20 and 40 minutes in Zimbabwe, and twice in Kenya at both 20 and 40 minutes to assess test performance at the lower and upper recommended times. OMT results were not shared with caregivers, because the test was undergoing validation.

Statistical Analysis

Data were analyzed using STATA 14 (StataCorp, College Station, TX). Sensitivity was calculated by dividing the number of OMT and BBT-positive children by the number of BBT-positive children. Specificity was calculated by dividing the number of OMT and BBT-negative children by the number of BBT-negative children. Positive predictive value (PPV) and negative predictive value (NPV) were calculated in the Zimbabwean cohort by dividing the number with both positive OMT and BBT by all the positive OMT tests (PPV) and by dividing the number with both negative OMT and BBT results by the total negative by OMT (NPV). PPV and NPV were not calculated in the Kenyan cohort, because positive children were oversampled. Ninety-five percent (95%) or 97.5% (when the estimate was 100%) confidence intervals (CIs) were calculated using a binomial distribution. Stability of the test results using result interpretation pictures from the manufacturer was described in Kenya.

Ethics

Adolescents ≥16 gave independent written informed consent without parental/guardian consent. Parents/guardians of children aged 18 months–15 years provided written consent; adolescents 13–15 years signed a paragraph within the parental consent form to give their assent, whereas children 7–12 years signed a separate assent document, which was optional in Kenya. B-GAP received approval from the Biomedical Research and Training Institute, the Medical Research Council of Zimbabwe and institutional review boards at Duke University and the London School of Hygiene and Tropical Medicine. The Kenyan study received approval from the Kenyatta National Hospital Ethics and Research Committee and the University of Washington Institutional Review Board.

RESULTS

Demographics

Overall, 1776 children were enrolled; 1570 (88%) from Zimbabwe and 206 (12%) from Kenya. The median age was 7.3 years (IQR: 4.7–11.6); 2 (0.1%) were 18 months–2 years; 512 (29%) were >2–5 years; 845 (48%) were >5–12 years; and 417 (23%) were >12–18 years. Overall, 918 (52%) were female. Among Kenyan children, 169 (82%) were identified via index case testing and 37 (18%) in outpatient clinics and inpatient wards (Table 1).

OMT Sensitivity and Specificity

Among 71 children positive by BBT, 71/71 (sensitivity: 100.0% [97.5% CI: 94.9% to 100.0%]) were positive by OMT. Among 1705 children negative by BBT, 1703/1705 (specificity: 99.9% [95% CI: 99.6% to 100.0%]) were negative by OMT. In the 1570 Zimbabwean participants, the PPV was 93.3% (95% CI: 77.9% to 99.2%) and the NPV was 100.0% (97.5% CI: 99.8% to 100.0%).

In Zimbabwe, 2 children who initially tested BBT-negative and OMT-positive were retested within 1 week to confirm HIV status because of suggestive clinical presentation and history; both were confirmed positive. A 9-year-old was confirmed positive by ELISA. A 2-year-old was confirmed positive by First Response and CHEMBIO. Excluding these 2 children, the sensitivity and specificity of OMT compared with those of BBT were each 100% (97.5% CI: 94.9% to 100% and 99.8% to 100%, respectively) (Table 2).
**TABLE 2. Performance of OMT vs BBT for HIV Diagnosis**

|                  | BBT                              |                |                |
|------------------|----------------------------------|----------------|----------------|
|                  | Positive                         | Negative       | N              |
| Panel A: Overall |                                  |                |                |
| Results          |                                  |                |                |
| OMT              |                                  |                |                |
| Positive         | 71                               | 2*             | 73             |
| Negative         | 0                                | 1703           | 1703           |
| Total            | 71                               | 1705           | 1776           |
| Sensitivity      | 100% (97.5% CI: 97.8 to 100)     |                |                |
| Specificity      | 99.9% (95% CI: 99.6 to 100)      |                |                |
| (including 2     |                                  |                |                |
| discrepants)     |                                  |                |                |
| Specificity      | 100% (97.5% CI: 99.8 to 100)     |                |                |
| (excluding 2     |                                  |                |                |
| discrepants)     |                                  |                |                |
| Panel B: Zimbabwe|                                  |                |                |
| OMT              |                                  |                |                |
| Positive         | 28                               | 2*             | 30             |
| Negative         | 0                                | 1540           | 1540           |
| Total            | 28                               | 1542           | 1570           |
| Sensitivity      | 100% (97.5% CI: 87.7 to 100)     |                |                |
| Specificity      | 99.9% (95% CI: 99.5 to 100)      |                |                |
| (including 2     |                                  |                |                |
| discrepants)     |                                  |                |                |
| Specificity      | 100% (97.5% CI: 99.8 to 100)     |                |                |
| (excluding 2     |                                  |                |                |
| discrepants)     |                                  |                |                |
| Panel C: Kenya   |                                  |                |                |
| OMT              |                                  |                |                |
| Positive         | 43                               | 0              | 43             |
| Negative         | 0                                | 163            | 163            |
| Total            | 43                               | 163            | 206            |
| Sensitivity      | 100% (97.5% CI: 91.8 to 100)     |                |                |
| Specificity      | 100% (97.5% CI: 97.8 to 100)     |                |                |
| (excluding 2     |                                  |                |                |
| discrepants)     |                                  |                |                |

*Subsequently confirmed as HIV-positive using additional tests within 1 week of initial testing.

**DISCUSSION**

In this cross-sectional study of children aged 18 months to 18 years, we found that OMT had excellent sensitivity and specificity. When compared to the Kenyan and Zimbabwean national algorithms, OMT did not miss any positive children. These data suggest that OMT is valid for HIV diagnosis in this age range.

As with other antibody tests, OMT is inappropriate as a diagnostic test for children under 18 months due to the presence of maternal antibodies. In adults, antibody-based tests have limitations due to a long window period, which may lead to failure in detecting recent HIV infection. However, this is of less of a concern among older children and younger adolescents who, if infected, are likely to have long-standing HIV, acquired perinatally.

Our results provide evidence for wider use of OMT for pediatric testing. Current testing approaches to identify children include index-linked testing, provider-initiated testing and counseling, targeted testing in health facilities, and community-based testing. Outpatient provider-initiated testing and counseling can identify children earlier in disease progression; however, achieving high coverage is challenging because of high client volume and workload for limited numbers of HCWs. In resource-limited settings, scaling up testing will require simultaneously increasing coverage and minimizing costly components of testing, including HCW time. The ease and safety of OMT presents a potential opportunity for task-shifting from HCWs to lay providers, as was done in this study, or to caregivers to overcome human resource constraints. It is also important to note that the time to perform OMT is similar to that required for BBT. Future research is needed to explore the acceptability and feasibility of OMT by caregivers and HCWs in facility and community settings.

A 2012 systematic review comparing OMT with whole blood specimens reported a pooled sensitivity of 98.0% and specificity of 99.7% for OMT. Despite this, the concentration of antibodies in oral fluid is lower than in blood and typically wanes during HIV treatment. Previous studies in Zimbabwe have confirmed that OMT has suboptimal sensitivity in ART-experienced children. WHO has issued warnings, advocating that rapid diagnostic tests not be used among ART-experienced adults; similar warnings seem warranted in children. Therefore, it is critical to avoid use of OMT by ART-experienced patients, either to confirm being "cured" of HIV or when reinitiating HIV care. Our study included an entirely ART-naïve pediatric population and observed no false-negative results. In 2 cases, children were negative by BBT and positive by OMT and were confirmed HIV-positive upon repeat testing. This suggests slightly better detection by OMT than BBT in our study; it is unclear why we observed this counterintuitive finding.

Our study’s strengths include a large sample of ART-naïve, HIV-positive children to inform precise estimates of sensitivity. In addition, data from Kenya and Zimbabwe provided similar results. OMT results were compared with routine, field-based BBT according to national algorithms, which provides an apt comparison with standard-of-care tests and provides useful public health information. Limitations include that OMT result interpretation was not blinded in Kenya, which may have influenced result interpretation. National algorithms between the 2 countries differed slightly, so the “reference standard” was not the same in both countries. However, in both cases, the algorithms are those used for national guidelines. Consequently, our findings demonstrate the performance of OMT against the standard-of-care and are therefore generalizable in these settings. Although the BBT in this study was not ELISA or polymerase chain reaction (PCR) based, OMT has previously been compared with these more sensitive lab-based tests to inform Food and Drug Administration approval and WHO
endorsement for use in adults. An additional limitation is that in our study we did not have any inconclusive test results. Procedures on how to report and manage inconclusive test results must be put in place.

CONCLUSIONS

OMT is highly sensitive and specific in children and adolescents. This is consistent with findings from studies in adult populations. Policymakers and regulators should consider expanding the age at which OMT may be used to include children over 18 months.

ACKNOWLEDGMENTS

The authors thank the B-GAP, STEP-UP, and FIT study staff and participants.

REFERENCES

1. UNAIDS. Global HIV & AIDS Statistics 2018 Fact Sheet UN. 2018.
2. Cotton MF, Violar i A, Otow ombe K, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013;382:1555–1563.
3. Low A, Gavr ilidis G, Larke N, et al. Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis. 2016;62:1595–1603.
4. Kellerman S, Essajee S. HIV testing for children in resource-limited settings: what are we waiting for? PLoS Med. 2010;7:e1000285.
5. Benki-Nugent S, Wamalwa D, Langat A, et al. Comparison of developmental milestone attainment in early-treated HIV-infected vs HIV-unexposed infants: a prospective cohort study. BMC Pediatr. 2017;17:24.
6. Chikwari CD, Dringus S, Ferrand RA. Barriers to, and emerging strategies for, HIV testing among adolescents in sub-Saharan Africa. Curr Opin HIV AIDS. 2018;13:257–264.
7. World Health Organization. Consolidated Guidelines on HIV Testing Service. 2015.
8. Mugo PM, Micheni M, Shangala J, et al. Uptake and acceptability of oral HIV self-testing among community pharmacy clients in Kenya: a feasibility study. PLoS One. 2017;12:e0170868.
9. Johnson CC, Kennedy C, Fonner V, et al. Examining the effects of HIV self-testing compared to standard HIV testing services: a systematic review and meta-analysis. J Int AIDS Soc. 2017;20:21594.
10. Pant Pai N, Balram B, Shivkumar S, et al. Head-to-head comparison of OraQuick ADVANCE Rapid HIV-1/2 Antibody Test. 2018; Available at: http://www.orasure.com/products-infectious/products-infectious-orauquick.asp. Accessed August 28, 2018.
11. Wagner AD, Njuguna IN, Neary J, et al. Financial incentives to increase uptake of pediatric HIV testing (FIT): study protocol for a randomised controlled trial in Kenya. BMJ Open. 2018;8:e024310.
12. Ministry of Health N. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV in Kenya. Nairobi, Kenya: Ministry of Health, NASCAP; 2018.
13. Orasure Technologies I. OraQuick ADVANCE Rapid HIV-1/2 Antibody Test. 2018; Available at: http://www.orasure.com/products-infectious/products-infectious-orauquick.asp. Accessed August 28, 2018.
14. Taylor D, Durigon M, Davis H, et al. Probability of a false-negative HIV antibody test result during the window period: a tool for pre- and post-test counselling. Int J STD AIDS. 2015;26:215–224.
15. Bandason T, McHugh G, Dauya E, et al. Validation of a screening tool to identify older children living with HIV in primary care facilities in high HIV prevalence settings. AIDS (London, England). 2016;30:779–785.
16. Ministry of Health N. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV in Kenya. Nairobi, Kenya: Ministry of Health, NASCAP; 2018.
17. Orasure Technologies I. OraQuick ADVANCE Rapid HIV-1/2 Antibody Test. 2018; Available at: http://www.orasure.com/products-infectious/products-infectious-orauquick.asp. Accessed August 28, 2018.
18. Sacks E, Cohn J, Penazzato M. HIV misdiagnosis in paediatrics: unpacking the complexity. J Int AIDS Soc. 2017:20(suppl 6):e21959.
19. Johnson CC, Fonner V, Sands A, et al. To err is human, to correct is public health: a systematic review examining poor quality testing and misdiagnosis of HIV status. J Int AIDS Soc. 2017:20(suppl 6):e21755.